Researchers looked for genetic predictors of how much weight people lose on GLP-1 receptor agonists and who gets side effects. The paper is open access.
Recap by typeshit. Post by @NatureAsia on X.
A short post credits scientists with finding axolotl peptides that kill breast cancer cells. It names no study or team, so treat it as an early claim.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
Researchers report that asprosin, a hunger hormone released by fat tissue, stays elevated after weight loss, which could help explain why lost pounds come back.
Nacionale covers research into whether GLP-1 drugs have effects reaching into criminal justice outcomes and how steadily people stay employed.
A Facebook post reports the TRIUMPH-2 result for Lilly's triple agonist in people with type 2 diabetes. Few details beyond the headline number are given.
Loading…